SII seeks inclusion of Covovax in CoWIN portal as booster dose for adults

Covovax is manufactured through technology transfer from Novavax

Press Trust of India New Delhi

A health worker inoculates a woman with a Covid-19 booster dose at a private hospital in New Delhi | Photo: PTI

Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.

The letter was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), they said.

The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two doses of either Covishield or Covaxin.

The DCGI's approval was based on recommendations by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation.

The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and also in children aged seven to 11 years on June 28 last year subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax.

Also Read

SII's Covid vaccine Covovax gets heterologous booster dose approval

Govt panel recommends market authorisation for Covovax jab as booster dose

Govt panel may decide on Covovax as heterologous booster dose for adults

Covovax to get approval as booster in 10-15 days, says SII CEO Poonawalla

Serum Institute plans pandemic facility to stockpile vax for the world

Paint industry could see further downsides on demand, competitive pressures

NCLT asks lenders to delay round of second auction for Reliance Capital

Land dispute case: SC orders DLF to pay Rs 235 crore to Noida Authority

Vedanta to acquire debt-laden Meenakshi Energy for Rs 1,440 crore

Microsoft to reduce 10,000 jobs globally amid bleak global outlook

It has been approved by the European Medicines Agency for conditional marketing authorization and was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.

In August 2020, US-based vaccine maker Novavax Inc. had earlier announced a licence agreement with the SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income countries.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Jan 18 2023 | 11:44 PM IST

Explore News